ADARx Pharmaceuticals, Inc. Stock: price and insider trades · United States
3 insiders bought €29.2M of shares over the last 90 days, the latest by Chimovits Erez, filed 30 Sept 2026.
Who traded when
BuySaleSince the insiders bought
- -12.3%Entry US$19.54 · Close 21 Oct 2026 US$17.13
- -12.3%Entry US$19.54 · Close 21 Oct 2026 US$17.13
- -14.1%Entry US$19.94 · Close 21 Oct 2026 US$17.13
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ADARx Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$34.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 61,516 shares@ US$17.00100.0% of flowCommon StockSEC:0000947871-26-000912:4Canonical exit: 27 Dec 2026 (T+90)
- 10,690,530 sharesCommon StockSEC:0000947871-26-000911:0
- 2,000,962 sharesCommon StockSEC:0000947871-26-000911:1
- 769,601 sharesCommon StockSEC:0000947871-26-000911:2
- 564,187 sharesCommon StockSEC:0000947871-26-000911:3
- 300,249 shares@ US$17.0031.6% of flowCommon StockSEC:0000947871-26-000911:4Canonical exit: 27 Dec 2026 (T+90)
- 7,127,019 sharesCommon StockSEC:0000947871-26-000911:5
- 1,333,975 sharesCommon StockSEC:0000947871-26-000911:6
- 513,067 sharesCommon StockSEC:0000947871-26-000911:7
- 256,448 sharesCommon StockSEC:0000947871-26-000911:8
- 588,235 shares@ US$17.0061.9% of flowCommon StockSEC:0000947871-26-000911:10Canonical exit: 27 Dec 2026 (T+90)
- 10,690,530 sharesCommon StockSEC:0000947871-26-000910:0
- 2,000,962 sharesCommon StockSEC:0000947871-26-000910:1
- 769,601 sharesCommon StockSEC:0000947871-26-000910:2
- 564,187 sharesCommon StockSEC:0000947871-26-000910:3
- 7,127,019 sharesCommon StockSEC:0000947871-26-000910:5
- 1,333,975 sharesCommon StockSEC:0000947871-26-000910:6
- 513,067 sharesCommon StockSEC:0000947871-26-000910:7
- 256,448 sharesCommon StockSEC:0000947871-26-000910:8
- 513,067 sharesCommon StockSEC:0000947871-26-000912:2
- 256,448 sharesCommon StockSEC:0000947871-26-000912:3
- 1,333,975 sharesCommon StockSEC:0000947871-26-000912:1
- 7,127,019 sharesCommon StockSEC:0000947871-26-000912:0
- 592,593 shares@ US$17.0058.8% of flowCommon StockSEC:0001193125-26-408061:3Canonical exit: 27 Dec 2026 (T+90)
- 1,538,691 sharesCommon StockSEC:0001193125-26-408061:4
25 of 43 declarations
About ADARx Pharmaceuticals, Inc.
All of the activity at ADARx Pharmaceuticals, Inc. falls on one day. On September 28, 2026, 5 purchases are recorded for EUR 29.2 million, from 3 filers, published on September 29 and 30, 2026: EUR 8.8 million and EUR 6.2 million for Simeon George (Director), and EUR 8.8 million for Carl L. Gordon (Director). The median purchase is EUR 6,192,219, and 5 filings belong to cluster purchases.
The record has 43 filings from 6 filers, all published in 2026 with a median delay of 2 days. 38 are neither purchases nor sales: Orbimed Advisors LLC (Director) filed 8, SR One Capital Management, LLC (10% Owner) 6 and LAV Biosciences Fund V, L.P. (10% Owner) 6. Carl L. Gordon filed 10, 2 of them purchases, and Simeon George filed 8, also 2 purchases. No sale is recorded.
Read moreShow less
This US healthcare company, listed on Nasdaq and valued at USD 1.9 billion, has 41.8% of its capital held by insiders. The last 12 months match the whole record: 43 filings, 5 purchases.
Written on 22 October 2026 from the filings and market data available that day. Live figures are in the blocks above.
The weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.
